Market closedNon-fractional
Treace Medical Concepts/TMCI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Treace Medical Concepts
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.
Ticker
TMCI
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Ponte Vedra, United States
Employees
516
Website
www.treace.com
TMCI Metrics
BasicAdvanced
$485M
Market cap
-
P/E ratio
-$0.89
EPS
0.37
Beta
-
Dividend rate
Price and volume
Market cap
$485M
Beta
0.37
Financial strength
Current ratio
3.983
Quick ratio
2.999
Long term debt to equity
54.79
Total debt to equity
55.473
Interest coverage (TTM)
-10.85%
Management effectiveness
Return on assets (TTM)
-14.33%
Return on equity (TTM)
-38.55%
Valuation
Price to revenue (TTM)
2.461
Price to book
3.84
Price to tangible book (TTM)
4.63
Price to free cash flow (TTM)
-12.55
Growth
Revenue change (TTM)
26.48%
Earnings per share change (TTM)
5.81%
3-year revenue growth (CAGR)
44.62%
3-year earnings per share growth (CAGR)
86.16%
What the Analysts think about TMCI
Analyst Ratings
Majority rating from 7 analysts.
TMCI Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$51M
-17.85%
Net income
-$19M
200.00%
Profit margin
-36.39%
265.36%
TMCI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.20
-$0.28
-$0.10
-$0.30
-
Expected
-$0.24
-$0.26
-$0.09
-$0.30
-$0.29
Surprise
-16.08%
7.10%
12.90%
-0.94%
-
TMCI News
AllArticlesVideos
Treace to Report Second Quarter 2024 Financial Results on August 6, 2024
GlobeNewsWire·1 week ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCI
PRNewsWire·2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCI
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Treace Medical Concepts stock?
Treace Medical Concepts (TMCI) has a market cap of $485M as of July 27, 2024.
What is the P/E ratio for Treace Medical Concepts stock?
The price to earnings (P/E) ratio for Treace Medical Concepts (TMCI) stock is 0 as of July 27, 2024.
Does Treace Medical Concepts stock pay dividends?
No, Treace Medical Concepts (TMCI) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Treace Medical Concepts dividend payment date?
Treace Medical Concepts (TMCI) stock does not pay dividends to its shareholders.
What is the beta indicator for Treace Medical Concepts?
Treace Medical Concepts (TMCI) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Treace Medical Concepts stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.